A well-recognized challenge in the US healthcare system is the consistent use of evidence in medical decision making.
1,2 A particular challenge for the healthcare provider and the patient is to choose among competing therapeutic approaches for a particular condition, e.g., choice of a particular drug for depression. Often, the relative benefits and risks of potential therapies are not uniformly available from the existing scientific information, a situation sometimes referred to as the "inferential gap." 3, 4 The availability of scientific information regarding effectiveness is more limited than information regarding efficacy, in part because studies designed for regulatory approval do not mirror "real-world" practice. 5 However, efficacy data may also be limited, depending on the type of intervention (drugs, medical devices, or surgical procedures), and the time that the intervention has been available and its degree of use. In addition, treatments that have demonstrated efficacy will not work for all patients. For some they may be ineffective or harmful, e.g., patients with comorbidities or different genetic compositions. For physicians and patients a key treatment question is often which of the several alternative treatments should be considered. Efficacy trials, randomized controlled trials (RCTs), usually exclude patients with comorbidities and therefore do not provide direct evidence relevant to the most challenging patient groups for healthcare providers to manage. RCTs are also often designed with intermediate measures as endpoints, and thus do not provide the information most desired by physicians, patients, and other medical decision makers. Additionally, short follow-up times do not allow appreciation of survival or longer-term outcome measures. The 2007 report from the Medicare Payment Advisory Commission concluded that there is not enough empirically based information for healthcare providers and patients to make informed treatment decisions. 6 The commission also noted that variations in care are high when evidence is unclear.
Comparative research is most often available for cardiovascular and endocrine conditions and least available for neurologic and pulmonary conditions. 7 There are several significant study design challenges in conducting comparative effectiveness research (CER) in general. In placebo-controlled trials a treatment is evaluated in comparison to an inert treatment. In active-controlled trials there is comparison of equivalence or noninferiority with a prespecified amount of a comparator and a treatment with known efficacy. 8 The most robust design in an active-controlled study is inclusion of a placebo group in a 3-arm design (when there is equipoise for this arm and therefore ethical acceptability). This design allows for direct demonstration of superiority in reference to the placebo. 9 For active-controlled trials, a new treatment should be compared with standard treatment when there is sufficient evidence such that it can serve as a reference treatment. The reference treatment should have a well-established predictable effect at the dose and protocol to be tested. Intensity of treatment and dose should be equipotent. The dose regimens also should be comparable, and trial endpoints should not favor a particular intervention.
It is important to guard against bias in comparative studies, especially when methods other than RCTs are used. Studies that rely only on administrative data may classify cases inappropriately owing to missing information or may lack information regarding relevant factors or exposures (i.e., information or selection bias). Lack of data on potential confounders (i.e., factors that are associated with treatment and outcome) may also be an issue. Uses of methods such as propensity scores and instrumental variables have been described as approaches that can mimic randomization. 10, 11 Propensity scores are a quasi-experimental correction strategy in which a predicted probability of group membership (control or experimental) is derived and may also be used for matching, or as a covariate. 12 Another quasi-experimental method is use of instrumental variables. 13 An instrumental variable is a variable that is correlated with the treatment and is related to the outcome only through the association with treatment. Further descriptions of these techniques are discussed by Concato and coworkers 14 elsewhere in this supplement. Regardless of the analysis approach used, the primary focus should be on reducing sources of bias (e.g., multiple exposure bias) and adjusting for confounding (e.g., adherence differences), rather than hoping for a "magic bullet" provided by the methodological approach. 15 At times, groups of studies with varying methodologies and approaches to patient follow-up may be appropriate.
The conduct of CER requires appropriate infrastructure for successful completion of studies. The Federal Coordinating Council for CER research outlined infrastructure needs for this research (Table 1) . Depending on the question and approach of the study various capabilities identified in Table 1 will be required. The US Department of Veterans Affairs (VA) has all of the aspects of the scientific infrastructure outlined in Table 1 . The VA is one of the largest organized health systems and has the largest medical education and health professions training programs in the United States. 16 The VA's medical facilities are affiliated with 107 medical schools, 55 dental schools, and Ͼ1,200 other schools. Roughly 90,000 health professionals are trained in the VA each year. The number of patients treated and medical facilities included in the Veterans Health System are indicated in Table 2 . The VA electronic health record is available at all sites of care.
CER with the greatest impact addresses questions that focus on gaps in existing evidence, and, when completed, provides timely information for medical decision making. 17 The goal of the research is to facilitate the best use of medical interventions or technologies, i.e., identifying which types of patients would most benefit from particular treatments. An Institute of Medicine (IOM) workshop held in 2001 highlighted the current deficiency and need for effectiveness research. 18 Following this workshop, members of the IOM Clinical Research Roundtable published recommendations regarding a definition of effectiveness research and mechanisms for research question formulation. 19 More recently, CER has received more attention, and a Patient-Centered Research Institute focusing on supporting CER was established as part of Public Law No: 111-148. SEC 6301, 2010.
The VA CER research program is unique because it is embedded within a national health system. The VA has the resources and infrastructure (including electronic health records, clinical research pharmacy, etc.) to fully support and execute CER research, including large multicenter clinical trials. Additionally, roughly 70% of VA researchers are also clinicians, exposing them to clinically relevant issues. The VA Cooperative Studies Program (CSP) provides a e4
The
platform to collaboratively identify and refine research questions, many of which are CER. To gather a better understanding of VA CER, we reviewed articles that had VA coauthors published in 2 leading medical journals to determine the proportion of CER, the types of comparisons, and the areas of focus. Titles and abstracts of articles were reviewed by the coauthors, and were identified as CER using the IOM definition. All studies in which there was a comparison with an active treatment were selected as comparative effectiveness studies. The comparator could involve a usual-care group if the usual care was well defined. All publications identified in the search included VA coauthors (n ϭ 335). Letters, editorials, and corrections were excluded from the count (n ϭ 184).
METHODS

RESULTS
There were 151 articles, reviews, or proceedings papers identified with VA coauthors (Table 3) . A total of 25% (n ϭ 38) were identified as CER studies. There was a wide variation in the types of interventions investigated, with pharmaceuticals as the most frequent category. Several studies involved varying types of intervention (e.g., behavior/drug or device/procedure). The distributions of the study topics are identified in Table 3 . The most frequent topic was cardiovascular disease. Examples of the identified CER studies are listed in Table 4 .
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DISCUSSION
The history of CER at the VA extends beyond 30 years.
27,28
The VA has a dedicated scientific infrastructure for conducting CER that is embedded within the healthcare system. The examples presented in Table 4 indicate, there is limited research devoted to assisting physicians in the effective use of therapies. Those unfamiliar with the Veterans Health Administration and VA research often assume that vast majority of research is focused solely on deployment issues. However, as indicated in Table 3 , and because of the spectrum of health issues faced by veterans, VA CER focuses on a variety of health issues relevant to the general US population. The mechanism for assuring the clinical relevance of these investigations is 2-fold. First, roughly 70% of VA investigators are also clinicians; thus, they are directly exposed to clinical needs. Second, the CSP, which supported many of the studies identified in this analysis, begins by identifying questions with high clinical relevance submitted by clinical proponents. 29 Involving these stakeholders both at the beginning and in consultations with the clinical system throughout the process appears to have benefited the program in terms of the timeliness and clinical relevance of research topics. Other important components are the fixed infrastructure support (e.g., coordinating and methodological centers, peer review) to help ensure the quality of the research. 30 The connection of the VA health system to VA research allows for the identification and study of important questions that are relevant to the health system but might not be raised by healthcare providers and manufacturers with financial interests in the technology or procedure. An example of a recent CER study is the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, which showed that the majority of patients with optimal medical therapy had substantial improvements in health status for Ͼ4 years. 26 The COURAGE findings are most applicable to patients with chronic stable chest pain. The implication for clinical practice is that use of percutaneous coronary intervention first should probably not be adopted for patients with stable angina. In the month following the publication of the article, US stent implants declined by 13%, but by 2009 the number of implants returned to previous levels. 31 These data point to the challenges in translating research into healthcare practice and in sustaining behavioral change. Evidence-based medical guidelines (EBM), based on empirical research, have been developed for many of the conditions identified in the IOM report Crossing the Quality Chasm: A New Health System for the 21st Century. 32 Yet, health services researchers and others have found that physicians and other healthcare providers frequently do not follow such guidelines. [33] [34] [35] Some of the obstacles to implementing EBM include the amount and complexity of research; limitations on clinicians' time; policies that do not encourage use of EBM; organizational barriers; lack of incentives to participate in educational activities; experiences, beliefs, and attitudes of healthcare providers that contradict EBM findings; local differences in healthcare delivery; and patient experience, beliefs, and attitudes that affect adherence. 36, 37 Variations in individual patients may also limit implementation of EBM. 38 The Quality Enhancement Research Initiative (QUERI) is focused directly on this implementation problem in the VA. 39 In the future, CER will be a much more prominent part of the research enterprise and it, in turn, will have many influences on both the research and clinical enterprises. The interest and movement toward CER will influence how research projects are identified and chosen, with more input from clinicians and the healthcare system as in the VA CSP. Also, recognition of the need for research efficiency will move the field beyond the RCT to other methodologies described above, though hopefully with great care.
Finally, CER will provide the information necessary to better inform choices for patients, providers, and the healthcare system. The choices will not only rely on CER, as it is currently considered, but on a complex of interacting and coalescing research vehicles. CER will be one such vehicle and personalized medicine, to address the issue of individual differences in response, another. Out of the synthesis will come vast improvement in our approach to the health of veterans and everyone else.
Joel Kupersmith, MD, has no financial arrangement or affiliation with a corporate organization or manufacturer of a product discussed in this article. 26 Optimal medical therapy vs.
percutaneous coronary intervention
The PCI group and medical-therapy group were comparable in the composite index of death, myocardial infarction, and stroke; hospitalization for ACS; or myocardial infarction ACS ϭ acute coronary syndromes; CBT ϭ cognitive behavioral therapy; EUC ϭ Enhanced usual care; PPI ϭ proton pump inhibitor.
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